---
title: "Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Co-prescribed/Concomitant therapies"
description: "Formulary evidence on Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Co-prescribed/Concomitant therapies. Topics: Background Huntington's disease medications: stable for 3 months before screening; Excluded prior and concurrent therapies; Immunosuppression regimen specified in the protocols; Immunosuppression at the discretion of the treating physician, October 2022; 2 further topics. 6 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description/co-prescribed-concomitant-therapies"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Co-prescribed/Concomitant therapies

<a id="heading-2.1.2.12"></a>

## 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

### Background Huntington's disease medications: stable for 3 months before screening

> “All HD concomitant medications (addressing motor, behavioral, and cognitive symptoms) must be stable for 3 months prior to Screening with no change in clinical symptoms requiring change in medication prior to anticipated administration procedure”

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

> “All HD concomitant medications (addressing motor, behavioral and cognitive symptoms) must be stable for 3 months prior to Screening with no change in clinical symptoms requiring change in medication prior to anticipated administration procedure.”

Source: [ClinicalTrials.gov NCT05243017](https://clinicaltrials.gov/study/NCT05243017)

<a id="topic-2.1.2.12-2"></a>

### Excluded prior and concurrent therapies

> “Receipt of an experimental agent within 60 days or five half-lives prior to Screening or anytime over the duration of this study.”
> “Participation in an investigational trial or investigational paradigm (such as exercise/physical activity, cognitive therapy, brain stimulation) within 60 days prior to Screening or anytime over the duration of this study.”
> “Any history of gene therapy, RNA or DNA targeted HD specific investigational agents, such as antisense oligonucleotides (ASOs), cell transplantation or any other experimental brain surgery.”

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

> “Patients may be ineligible to receive another gene therapy treatment after receiving AMT-130.”

Source: [uniQure Phase I/II clinical trial page](https://www.uniqure.com/programs-pipeline/phase-1-2-clinical-trial-of-amt-130)

<a id="topic-2.1.2.12-3"></a>

### Immunosuppression regimen specified in the protocols

> “Known allergy, sensitivity, or other contraindication to medications in the immunosuppression regimen in this protocol.”

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

> “Known immunocompromised status including participants who have undergone organ transplantation or who test positive at Screening for the human immunodeficiency virus (HIV); or who are at risk of pathogen reactivation if immunosuppressed, including participants who test positive at screening for hepatitis C virus antibody (anti-HCV), hepatitis C virus ribonucleic acid (HCV RNA), hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (anti-HBc); or who have history of active tuberculosis or a positive tuberculosis blood test during screening.”

Source: [ClinicalTrials.gov NCT05243017](https://clinicaltrials.gov/study/NCT05243017)

<a id="topic-2.1.2.12-4"></a>

### Immunosuppression at the discretion of the treating physician, October 2022

> “The DSMB also made no change to the treatment protocol regarding the use of immunosuppression that will continue to be at the discretion of the treating physician.”

Source: [uniQure press release, third quarter 2022 results (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-third-quarter-2022-financial-results-and)

<a id="topic-2.1.2.12-5"></a>

### Perioperative immunosuppression and steroids given with administration, 2023

> “All four crossover patients (3 high dose, 1 low dose) received a short course of immunosuppression therapy concurrent with the administration of AMT-130.”

Source: [uniQure press release, U.S. interim data (2023)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-us-phase-iii-clinical-trial-amt-130)

> “Additionally, six high-dose patients have received perioperative steroids with the administration of AMT-130 to reduce the risk of inflammation.”

Source: [uniQure press release, interim data update (2023)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-phase-iii-clinical-trials-amt-130-gene)

> “In 2023, we initiated patient dosing in a third cohort consisting of up to 12 patients to further investigate both doses of AMT-130 together with perioperative immunosuppression using the current, established stereotactic administration procedure.”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

<a id="topic-2.1.2.12-6"></a>

### Prophylactic short-term steroid regimen, May 2025

> “The Company expects a short-term steroid regimen will be incorporated as a prophylactic immunosuppression strategy.”

Source: [uniQure press release, second quarter 2025 results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-second-quarter-2025-financial-results-and)

> “In February 2025, we completed enrollment in a third cohort investigating an optimized immunosuppression regimen.”

Source: [uniQure Phase I/II clinical trial page](https://www.uniqure.com/programs-pipeline/phase-1-2-clinical-trial-of-amt-130)

<a id="topic-2.1.2.12-7"></a>

### Agents, doses, and duration of the immunosuppression regimen

No evidence found.

## Related pages
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Terms and abbreviations](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations.md)
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Product information and disease description](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Clinical evidence](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic information and modeling report](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: References](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references.md)
